Payment overview · 2025
General Payments
$625.61
39 reported records · 13 companies
Healthcare provider profile · identity verified
Adam M Vargo, MD
Allopathic & Osteopathic Physicians|Family Medicine · HARRISBURG, IL · NPI 1861683187
Verified facts
What the public records show
CMS Open Payments records show Adam M Vargo, MD received $625.61 in general payments during 2025 across 39 reported records.
ABBVIE INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.79 | 29.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.90 | 12.0% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $66.20 | 10.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.14 | 9.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.77 | 8.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.52 | 7.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.58 | 6.3% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $22.09 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.57 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.06 | 2.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.69 | 2.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.19 | 2.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $9.11 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $625.61 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $112.61 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.18 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $66.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.14 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $53.32 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.77 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.52 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.58 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $9.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
174 | 35 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1031 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 844 | 207 |
| Lisinopril | Lisinopril | 677 | 164 |
| Lorazepam | Lorazepam | 529 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 516 | 104 |
| Gabapentin | Gabapentin | 485 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 480 | 100 |
| Furosemide | Furosemide | 409 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 98 |
| Metformin Hcl | Metformin Hcl | 385 | 92 |
| Alprazolam | Alprazolam | 379 | 63 |
| Losartan Potassium | Losartan Potassium | 378 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 378 | 84 |
| Tramadol Hcl | Tramadol Hcl | 373 | 82 |
| Famotidine | Famotidine | 360 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 324 | 73 |
| Omeprazole | Omeprazole | 288 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 253 | 45 |
| Prednisone | Prednisone | 239 | 146 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 59 |
| Atenolol | Atenolol | 233 | 53 |
| Meloxicam | Meloxicam | 231 | 63 |
| Carvedilol | Carvedilol | 227 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 58 |
| Glipizide | Glipizide | 209 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 199 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 194 | 37 |
| Simvastatin | Simvastatin | 181 | 43 |
| Eliquis | Apixaban | 174 | 35 |
| Potassium Chloride | Potassium Chloride | 171 | 43 |
| Sertraline Hcl | Sertraline Hcl | 171 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 36 |
| Glimepiride | Glimepiride | 161 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 149 | 29 |
| Meclizine Hcl | Meclizine Hcl | 148 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 142 | 22 |
| Spironolactone | Spironolactone | 139 | 23 |
| Clonazepam | Clonazepam | 138 | 28 |
| Donepezil Hcl | Donepezil Hcl | 131 | 21 |
| Pregabalin | Pregabalin | 131 | 24 |
| Montelukast Sodium | Montelukast Sodium | 129 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 120 | 23 |
| Jardiance | Empagliflozin | 113 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 113 | 22 |
| Lovastatin | Lovastatin | 110 | 23 |
| Warfarin Sodium | Warfarin Sodium | 110 | 21 |
| Januvia | Sitagliptin Phosphate | 107 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 105 | 88 |
| Clonidine Hcl | Clonidine Hcl | 102 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 21 |
| Tradjenta | Linagliptin | 101 | 14 |
| Ibuprofen | Ibuprofen | 94 | 16 |
| Ozempic | Semaglutide | 90 | 19 |
| Allopurinol | Allopurinol | 88 | 28 |
| Celecoxib | Celecoxib | 85 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 83 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 83 | 24 |
| Synthroid | Levothyroxine Sodium | 80 | 19 |
| Ezetimibe | Ezetimibe | 79 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 15 |
| Baclofen | Baclofen | 74 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 73 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 73 | 55 |
| Temazepam | Temazepam | 70 | 13 |
| Diazepam | Diazepam | 69 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 13 |
| Buspirone Hcl | Buspirone Hcl | 64 | 18 |
| Trulicity | Dulaglutide | 64 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 11 |
| Metformin Hcl Er | Metformin Hcl | 61 | 14 |
| Alendronate Sodium | Alendronate Sodium | 60 | 12 |
| Trazodone Hcl | Trazodone Hcl | 60 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 12 |
| Terazosin Hcl | Terazosin Hcl | 58 | 11 |
| Topiramate | Topiramate | 58 | suppressed |
| Azithromycin | Azithromycin | 56 | 46 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 13 |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 12 |
| Nystatin | Nystatin | 54 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 12 |
| Nabumetone | Nabumetone | 53 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 46 |
| Fluconazole | Fluconazole | 51 | 29 |
| Mupirocin | Mupirocin | 51 | 22 |
| Ondansetron Odt | Ondansetron | 51 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 11 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 44 | 11 |
| Naproxen | Naproxen | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 41 | 15 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 34 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | 16 |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Valsartan | Valsartan | 35 | 11 |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 15 |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Nexium | Esomeprazole Magnesium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Febuxostat | Febuxostat | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Armodafinil | Armodafinil | 14 | suppressed |
| Humira(Cf) Pen | Adalimumab | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $625.61 · 39 records | ABBVIE INC. | AIRSUPRA, BREZTRI, BRIXADI, Cologuard Collection Kit, GEMTESA, JOURNAVX, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, Sunosi, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error